Managing Missed Doses of Wegovy (Semaglutide 2.4 mg)
Direct Recommendation
If a patient misses two consecutive weekly injections of Wegovy, resume at the same dose if the medication was previously well-tolerated, rather than restarting the entire titration schedule. 1, 2
Detailed Guidance for Two Missed Doses
Resume at Current Dose
Clinical judgment supports continuing at the same dose after missing 1–2 consecutive injections, provided the patient tolerated that dose well before the interruption. 1, 2
Administer the missed dose as soon as possible if fewer than 5 days have elapsed since the scheduled injection day, then return to the regular weekly schedule. 3
If more than 5 days have passed since the missed dose, skip it entirely and administer the next dose on the regularly scheduled day. 3
Rationale for Same-Dose Resumption
Semaglutide has a half-life of approximately one week, maintaining therapeutic drug levels for several days after a missed dose, which supports resuming at the current dose rather than down-titrating. 1
Two weeks of missed therapy does not fully reset gastrointestinal tolerance in the way that a 6-month interruption would, so the patient retains adaptation to the current dose. 4
When to Restart Titration Schedule
Three or More Missed Doses
If the patient misses ≥3 consecutive weekly injections (i.e., three weeks or more), consider restarting the full titration schedule beginning at 0.25 mg weekly to minimize gastrointestinal adverse events. 1, 2
Restarting titration after prolonged interruption reduces the risk of severe nausea, vomiting, and treatment discontinuation, which occur at markedly higher rates when patients resume directly at maintenance doses. 4
Monitoring After Resumption
Gastrointestinal Tolerance
Nausea, vomiting, and diarrhea are the most common adverse effects of semaglutide, occurring in 18–40%, 8–16%, and ~12% of patients, respectively; these are dose-dependent and typically transient. 1, 2, 5
Slow dose titration minimizes gastrointestinal side effects; if the patient experiences significant nausea after resuming, consider temporarily reducing the dose by one step (e.g., from 2.4 mg to 1.7 mg) for 4 weeks before re-escalating. 1, 2
Weight and Efficacy
Evaluate treatment response at 12–16 weeks on the maximum tolerated dose; discontinue therapy if weight loss is <5% after 3 months, as early non-responders are unlikely to benefit from continued use. 1
In real-world settings, patients on semaglutide 2.4 mg achieve mean weight loss of 13.4% at 6 months, 17.6% at 12 months, and 20.4% at 24 months when combined with lifestyle intervention and patient support programs. 6
Safety Considerations
Pancreatitis Warning
Instruct patients to discontinue Wegovy immediately and seek medical attention if they develop persistent severe abdominal pain, which may indicate pancreatitis (though causality has not been definitively established). 1, 3, 7
Regular monitoring of serum lipase is not routinely required, but clinicians should maintain a high index of suspicion for pancreatitis in patients reporting abdominal symptoms. 7
Hypoglycemia Risk
Semaglutide carries minimal intrinsic hypoglycemia risk when used as monotherapy, but caution is required when combined with insulin or insulin secretagogues (e.g., sulfonylureas). 1, 2
If the patient is on concomitant insulin or sulfonylureas, do not adjust these medications solely because of two missed Wegovy doses; however, monitor blood glucose closely during the first week after resumption. 1
Drug Interactions and Contraindications
Medication Interactions
Semaglutide delays gastric emptying, which may affect the absorption of oral medications; however, this effect is already present in patients on chronic therapy and does not require special management after two missed doses. 2
Do not combine Wegovy with other GLP-1 receptor agonists or DPP-4 inhibitors, as concurrent use provides no additional benefit and increases adverse-event burden. 1, 2
Absolute Contraindications
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2) is an absolute contraindication to semaglutide, based on animal studies showing thyroid C-cell tumors. 1, 3
Common Pitfalls to Avoid
Do not restart the entire titration schedule (beginning at 0.25 mg) after only two missed doses; this unnecessarily delays therapeutic benefit and prolongs the time to reach the maintenance dose. 1, 2, 4
Do not assume that missing two doses requires medical evaluation or dose adjustment in asymptomatic patients; simply resume the regular schedule as outlined above. 2, 3
Do not administer a "catch-up" double dose to compensate for missed injections; this markedly increases the risk of severe gastrointestinal adverse events. 3
Do not discontinue therapy prematurely due to mild, transient nausea after resumption; these symptoms typically resolve within 4–8 weeks and can be managed with dietary modifications (smaller meals, avoiding high-fat foods). 1, 5
Patient Counseling Points
Advise patients to set a weekly reminder (e.g., smartphone alarm) to minimize missed doses, as adherence is critical for sustained weight loss and cardiometabolic benefits. 2
Educate patients that if they miss a dose, they should take it as soon as they remember—provided it is within 5 days of the scheduled day—and then return to their regular weekly schedule. 3
Reassure patients that missing one or two doses does not "reset" their progress or require starting over, which may reduce anxiety and improve long-term adherence. 2